Gene: FLT3

2322
CD135|FLK-2|FLK2|STK1
fms related tyrosine kinase 3
protein-coding
13q12.2
Ensembl:ENSG00000122025 MIM:136351 Vega:OTTHUMG00000016646 UniprotKB:P36888
NG_007066.1
PubMed|SNP Mapped
2   ANCO-SNPs
ND|AD
2   
1.662e-1 (AD)  9.608e-1 (ND)   (Frontal_Cortex)
7.545e-2 (AD)  2.217e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs7317159chr13:28012083 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs17086213chr13:28010607 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
COL12A10.713
ICA10.708
GLMN0.701
ASAH2B0.698
SLC26A40.695
CAPS20.691
RBM110.688
ZNF250.688
EIF5A20.687
TASP10.686

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CCDC102A-0.473
SYDE1-0.456
WDR38-0.452
ATOH8-0.448
HVCN1-0.446
AKR1C3-0.44
RAB13-0.433
RHOD-0.426
SH2D4A-0.425
FOXJ1-0.421

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00398SorafenibSmall Molecule284461-73-0Approved|InvestigationalTarget
DB01268SunitinibSmall Molecule557795-19-4Approved|InvestigationalTarget
DB05014XL999Small Molecule921206-68-0InvestigationalTarget
DB05465TandutinibSmall Molecule387867-13-2InvestigationalTarget
DB06080ABT-869Small Molecule-InvestigationalTarget
DB06469LestaurtinibSmall Molecule111358-88-4InvestigationalTarget
DB06595MidostaurinSmall Molecule120685-11-2Approved|InvestigationalTarget
DB08901PonatinibSmall Molecule943319-70-8Approved|InvestigationalTarget
DB09079NintedanibSmall Molecule656247-17-5ApprovedTarget
DB12267BrigatinibSmall Molecule1197953-54-0Approved|InvestigationalTarget
DB12742AmuvatinibSmall Molecule850879-09-3InvestigationalTarget
DB12874QuizartinibSmall Molecule950769-58-1InvestigationalTarget
ID Drug Name Action PubMed
C56123411-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene"11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene results in decreased activity of FLT3 protein"21604762
C0005892902-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4',3'-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone"2-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4',3'-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone results in decreased phosphorylation of FLT3 protein"24526162
C0005892902-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4',3'-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone"2-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4',3'-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone results in decreased activity of FLT3 protein"24526162
C5495694-cyano-N-(2-(1-cyclohexen-1-yl)-4-(1-((dimethylamino)acetyl)-4-piperidinyl)phenyl)-1H-imidazole-2-carboxamide4-cyano-N-(2-(1-cyclohexen-1-yl)-4-(1-((dimethylamino)acetyl)-4-piperidinyl)phenyl)-1H-imidazole-2-carboxamide results in decreased activity of FLT3 protein22039836
C5139355-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide"5-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide results in decreased phosphorylation of FLT3 protein"17537993
C5610525H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one"5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one results in decreased activity of FLT3 protein"21608528
D000082AcetaminophenAcetaminophen affects the expression of FLT3 mRNA17562736
D0150812-Naphthylamine2-Naphthylamine results in decreased expression of FLT3 mRNA18247414
D000643Ammonium ChlorideAmmonium Chloride affects the expression of FLT3 mRNA16483693
C006632arsenic trioxidearsenic trioxide results in decreased phosphorylation of FLT3 protein17121903
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FLT3 mRNA18247414
C006780bisphenol Abisphenol A results in decreased expression of FLT3 mRNA25181051
D000001Calcimycinfulvic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of FLT3 mRNA]21331654
D000001Calcimycin[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of FLT3 mRNA21331654
C463260D-65476FLT3 gene mutant form promotes the reaction [[D-65476 co-treated with Tretinoin] results in decreased expression of BIRC5 mRNA]16473406
C463260D-65476FLT3 gene mutant form promotes the reaction [[D-65476 co-treated with Tretinoin] results in decreased expression of BIRC5 protein]16473406
D000069439DasatinibDasatinib results in decreased phosphorylation of FLT3 protein20145167
D002945CisplatinCisplatin results in increased expression of FLT3 mRNA27594783
D004041Dietary FatsDietary Fats results in increased expression of FLT3 mRNA25016146
D0150732-Acetylaminofluorene2-Acetylaminofluorene affects the expression of FLT3 mRNA18031378
D004397FonofosFonofos results in increased methylation of FLT3 promoter22847954
C005023fulvic acidfulvic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of FLT3 mRNA]21331654
C039281furanfuran results in increased expression of FLT3 mRNA27387713
C106014geduningedunin results in decreased expression of FLT3 protein17010675
C552521HG-7-85-01 compoundFLT3 protein results in decreased susceptibility to HG-7-85-01 compound21980431
C552521HG-7-85-01 compoundHG-7-85-01 compound results in decreased activity of FLT3 protein21980431
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FLT3 mRNA25613284
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of FLT3 mRNA"24972896
D008713MethimazoleMethimazole results in decreased expression of FLT3 mRNA22504374
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of FLT3 mRNA26011545
C059539midostaurinFLT3 protein results in decreased susceptibility to midostaurin21980431
C059539midostaurinmidostaurin results in decreased activity of FLT3 protein21980431
C568953N3-(4-(4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1H-1,2,4-triazole-3,5-diamine"N3-(4-(4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1H-1,2,4-triazole-3,5-diamine results in decreased activity of FLT3 protein"21970471
D037742Nanotubes, Carbon"Nanotubes, Carbon affects the expression of FLT3 mRNA"23845593
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of FLT3 mRNA"25554681
D009538NicotineNicotine results in decreased expression of FLT3 mRNA18247414
C500026palbociclibFLT3 protein affects the susceptibility to palbociclib27099147
C500026palbociclib[FLT3 protein affects the susceptibility to palbociclib] which results in decreased expression of FLT3 protein27099147
C500026palbociclibpalbociclib results in decreased expression of FLT3 mRNA27099147
C500026palbociclibpalbociclib results in decreased expression of FLT3 protein27099147
C500026palbociclibpalbociclib results in decreased phosphorylation of FLT3 protein27099147
D010278ParathionParathion results in increased methylation of FLT3 promoter22847954
C002669parthenolideparthenolide promotes the reaction [SC-203048 results in decreased expression of FLT3 mRNA]21928377
C545373ponatinibponatinib analog results in decreased activity of FLT3 protein21561767
C545373ponatinibponatinib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form]22409268
C545373ponatinibponatinib results in decreased activity of FLT3 protein19878872
C545373ponatinibponatinib results in decreased activity of FLT3 protein mutant form22409268
C545373ponatinibponatinib results in decreased phosphorylation of FLT3 protein mutant form21482694
C545373ponatinibponatinib results in decreased activity of FLT3 protein25053825
D011441PropylthiouracilPropylthiouracil results in decreased expression of FLT3 mRNA22504374|2478091
C572332SC-203048parthenolide promotes the reaction [SC-203048 results in decreased expression of FLT3 mRNA]21928377
C572332SC-203048SC-203048 results in decreased activity of FLT3 protein21928377
C572332SC-203048SC-203048 results in decreased expression of FLT3 mRNA21928377
C116890SemaxinibSemaxinib results in decreased activity of FLT3 protein12649163|1267371
C017947sodium arsenitesodium arsenite results in increased expression of FLT3 mRNA17879257
C017947sodium arsenitesodium arsenite results in increased phosphorylation of FLT3 protein20043101
C471405sorafenibFLT3 protein results in increased susceptibility to sorafenib23036488
C471405sorafenibsorafenib inhibits the reaction [FLT3 protein mutant form results in increased phosphorylation of FLT3 protein mutant form]22409268
C471405sorafenibsorafenib results in decreased activity of FLT3 protein17205056
C471405sorafenibsorafenib results in decreased activity of FLT3 protein mutant form17205056|1722963
C471405sorafenib[sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of FLT3 protein mutant form17205056
C471405sorafenib[sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK1 protein17205056
C471405sorafenib[sorafenib results in decreased activity of FLT3 protein mutant form] which results in decreased phosphorylation of MAPK3 protein17205056
C471405sorafenib[sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of FLT3 protein17205056
C471405sorafenib[sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK1 protein17205056
C471405sorafenib[sorafenib results in decreased activity of FLT3 protein] which results in decreased phosphorylation of MAPK3 protein17205056
C471405sorafenibsorafenib results in decreased phosphorylation of FLT3 protein mutant form21482694
C471405sorafenibsorafenib results in decreased activity of FLT3 protein20616376
C474557SU 11657SU 11657 results in decreased activity of FLT3 protein17184839
C416849SU 5614SU 5614 results in decreased activity of FLT3 protein16038735
C473478sunitinibsunitinib results in decreased phosphorylation of FLT3 protein mutant form21482694
C473478sunitinibsunitinib results in decreased activity of FLT3 protein20616376
C112765tanespimycintanespimycin results in decreased expression of FLT3 protein17010675
C012568terbufosterbufos results in increased methylation of FLT3 promoter22847954
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FLT3 mRNA26377647
D013755Tetradecanoylphorbol Acetatefulvic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of FLT3 mRNA]21331654
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of FLT3 mRNA21331654
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FLT3 mRNA25613284
C475928THRX 165724THRX 165724 results in decreased phosphorylation of FLT3 protein17537993
D014118Toxins, Biological"Toxins, Biological affects the expression of FLT3 mRNA"19682533
D014212TretinoinFLT3 gene mutant form promotes the reaction [[D-65476 co-treated with Tretinoin] results in decreased expression of BIRC5 mRNA]16473406
D014212TretinoinFLT3 gene mutant form promotes the reaction [[D-65476 co-treated with Tretinoin] results in decreased expression of BIRC5 protein]16473406
D014212TretinoinFLT3 protein mutant form results in increased susceptibility to Tretinoin16473406
C050414tripterinetripterine results in decreased expression of FLT3 protein17010675

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004709MAP kinase kinase kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IBA21873635  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IBA21873635  
GO:0004714transmembrane receptor protein tyrosine kinase activity-TAS19549778  
GO:0004888transmembrane signaling receptor activity-IBA21873635  
GO:0004896cytokine receptor activity-ISS-  
GO:0005021vascular endothelial growth factor-activated receptor activity-TAS8394751  
GO:0005515protein binding-IPI16982329  20098747  23246379  23650535  24525236  
GO:0005524ATP binding-IEA-  
GO:0019838growth factor binding-IBA21873635  
GO:0031434mitogen-activated protein kinase kinase binding-IBA21873635  
GO:0035259glucocorticoid receptor binding-IEA-  
GO:0042803protein homodimerization activity-TAS19549778  
GO:0043621protein self-association-IMP14759363  
GO:0044877protein-containing complex binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001776leukocyte homeostasis-ISS-  
GO:0002318myeloid progenitor cell differentiation-ISS-  
GO:0002328pro-B cell differentiation-ISS-  
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway-TAS7507245  
GO:0007275multicellular organism development-IBA21873635  
GO:0008284positive regulation of cell proliferation-TAS19549778  
GO:0009968negative regulation of signal transduction-IBA21873635  
GO:0010243response to organonitrogen compound-IEA-  
GO:0014068positive regulation of phosphatidylinositol 3-kinase signaling-TAS12951584  
GO:0018108peptidyl-tyrosine phosphorylation-TAS19549778  
GO:0019221cytokine-mediated signaling pathway-ISS-  
GO:0019221cytokine-mediated signaling pathway-TAS-  
GO:0030097hemopoiesis-IDA7507245  
GO:0030154cell differentiation-IBA21873635  
GO:0030183B cell differentiation-ISS-  
GO:0031100animal organ regeneration-IEA-  
GO:0033674positive regulation of kinase activity-IBA21873635  
GO:0035726common myeloid progenitor cell proliferation-ISS-  
GO:0038084vascular endothelial growth factor signaling pathway-IEA-  
GO:0042531positive regulation of tyrosine phosphorylation of STAT protein-TAS19549778  
GO:0042981regulation of apoptotic process-TAS19549778  
GO:0043066negative regulation of apoptotic process-IBA21873635  
GO:0043406positive regulation of MAP kinase activity-TAS19549778  
GO:0043410positive regulation of MAPK cascade-IBA21873635  
GO:0043410positive regulation of MAPK cascade-TAS19549778  
GO:0043552positive regulation of phosphatidylinositol 3-kinase activity-TAS12951584  
GO:0046651lymphocyte proliferation-ISS-  
GO:0046777protein autophosphorylation-TAS19549778  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IBA21873635  
GO:0071345cellular response to cytokine stimulus-ISS-  
GO:0071345cellular response to cytokine stimulus-TAS19549778  
GO:0071385cellular response to glucocorticoid stimulus-IEA-  
GO:0097028dendritic cell differentiation-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IEA-  
GO:0005737cytoplasm-IBA21873635  
GO:0005783endoplasmic reticulum-IDA-  
GO:0005788endoplasmic reticulum lumen-IEA-  
GO:0005829cytosol-IEA-  
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-TAS8394751  
GO:0032991protein-containing complex-IEA-  
GO:0043235receptor complex-IBA21873635  
KEGG ID KEGG Term
hsa04060Cytokine-cytokine receptor interaction
hsa04640Hematopoietic cell lineage
hsa05200Pathways in cancer
hsa05221Acute myeloid leukemia
Reactome ID Reactome Term Evidence
R-HSA-1280215Cytokine Signaling in Immune systemTAS
R-HSA-168256Immune SystemTAS
R-HSA-449147Signaling by InterleukinsTAS
R-HSA-449836Other interleukin signalingTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24571676RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures. (2014 Feb 26)Andrade FGBMC Cancer
12468438CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. (2003 Apr 1)Bowen DTBlood